Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AADI NASDAQ:ALT NASDAQ:NAGE NASDAQ:RCKT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$3.97+0.8%$3.69$1.21▼$3.81$98.05M0.68261,100 shs53,999 shsALTAltimmune$3.09+1.6%$3.42$2.56▼$7.73$395.52M0.185.50 million shs2.85 million shsNAGENiagen Bioscience$4.17-0.5%$4.74$4.04▼$14.69$333.71M2.17776,199 shs1.79 million shsRCKTRocket Pharmaceuticals$3.63-1.1%$4.09$2.19▼$7.39$400.48M0.522.13 million shs3.68 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+2.72%+20.99%+50.36%+162.66%ALTAltimmune0.00%+16.92%-9.79%-37.58%-43.28%NAGENiagen Bioscience0.00%-11.42%-8.91%-19.42%-50.41%RCKTRocket Pharmaceuticals0.00%+5.46%+1.94%+16.14%-45.02%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAADIAadi Bioscience$3.97+0.8%$3.69$1.21▼$3.81$98.05M0.68261,100 shs53,999 shsALTAltimmune$3.09+1.6%$3.42$2.56▼$7.73$395.52M0.185.50 million shs2.85 million shsNAGENiagen Bioscience$4.17-0.5%$4.74$4.04▼$14.69$333.71M2.17776,199 shs1.79 million shsRCKTRocket Pharmaceuticals$3.63-1.1%$4.09$2.19▼$7.39$400.48M0.522.13 million shs3.68 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAADIAadi Bioscience0.00%+2.72%+20.99%+50.36%+162.66%ALTAltimmune0.00%+16.92%-9.79%-37.58%-43.28%NAGENiagen Bioscience0.00%-11.42%-8.91%-19.42%-50.41%RCKTRocket Pharmaceuticals0.00%+5.46%+1.94%+16.14%-45.02%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAADIAadi Bioscience 0.00N/AN/AN/AALTAltimmune 2.50Moderate Buy$18.00482.52% UpsideNAGENiagen Bioscience 2.75Moderate Buy$15.00259.71% UpsideRCKTRocket Pharmaceuticals 2.39Hold$11.54217.86% UpsideCurrent Analyst Ratings BreakdownLatest AADI, RCKT, ALT, and NAGE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/5/2026NAGENiagen Bioscience Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $10.004/24/2026RCKTRocket Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/21/2026NAGENiagen Bioscience Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)3/31/2026NAGENiagen Bioscience Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.003/30/2026RCKTRocket Pharmaceuticals Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $9.003/27/2026ALTAltimmune Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/27/2026RCKTRocket Pharmaceuticals Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$11.003/18/2026ALTAltimmune Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.003/16/2026ALTAltimmune HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$12.00 ➝ $25.003/6/2026ALTAltimmune B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$18.00 ➝ $13.003/5/2026ALTAltimmune William BlairSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAADIAadi Bioscience$25.07M3.91N/AN/A$4.29 per share0.93ALTAltimmune$40K10,050.23N/AN/A$1.99 per share1.55NAGENiagen Bioscience$129.42M2.57$0.20 per share20.66$1.03 per share4.05RCKTRocket PharmaceuticalsN/AN/AN/AN/A$2.56 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAADIAadi Bioscience-$65.76M-$2.35N/AN/AN/A-246.06%-71.87%-57.28%N/AALTAltimmune-$88.09M-$1.01N/AN/AN/A-214,860.98%-49.35%-41.65%5/12/2026 (Estimated)NAGENiagen Bioscience$17.38M$0.2119.8615.44N/A14.29%22.68%16.23%N/ARCKTRocket Pharmaceuticals-$223.12M-$2.01N/AN/AN/AN/A-65.36%-55.18%5/14/2026 (Estimated)Latest AADI, RCKT, ALT, and NAGE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026ALTAltimmune-$0.25N/AN/AN/A$0.00 millionN/A5/7/2026Q1 2026RCKTRocket Pharmaceuticals-$0.41-$0.42-$0.01-$0.42$4.47 millionN/A5/6/2026Q1 2026NAGENiagen Bioscience$0.06$0.07+$0.01$0.07N/A$31.47 million3/5/2026Q4 2025ALTAltimmune-$0.25-$0.2719-$0.0219-$0.27$0.00 million$0.03 million2/26/2026Q4 2025RCKTRocket Pharmaceuticals-$0.42-$0.38+$0.04-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAADIAadi BioscienceN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/ANAGENiagen BioscienceN/AN/AN/AN/AN/ARCKTRocket PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAADIAadi BioscienceN/A4.894.54ALTAltimmune0.1518.5518.55NAGENiagen BioscienceN/A4.613.83RCKTRocket Pharmaceuticals0.076.386.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAADIAadi Bioscience52.08%ALTAltimmune78.05%NAGENiagen Bioscience15.41%RCKTRocket Pharmaceuticals98.39%Insider OwnershipCompanyInsider OwnershipAADIAadi Bioscience37.30%ALTAltimmune1.60%NAGENiagen Bioscience9.39%RCKTRocket Pharmaceuticals21.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAADIAadi Bioscience4024.70 million15.49 millionNo DataALTAltimmune50130.10 million128.02 millionOptionableNAGENiagen Bioscience12079.64 million72.17 millionN/ARCKTRocket Pharmaceuticals240109.12 million85.88 millionOptionableAADI, RCKT, ALT, and NAGE HeadlinesRecent News About These CompaniesRocket Pharmaceuticals (RCKT) Projected to Post Quarterly Earnings on ThursdayMay 7 at 4:05 AM | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and TriSalus Life Sciences (TLSI)April 29, 2026 | theglobeandmail.comRocket Pharmaceuticals Announces $180 Million Sale of Priority Review VoucherApril 28, 2026 | joplinglobe.comJLifesci Capital Has Pessimistic Outlook of RCKT Q1 EarningsApril 21, 2026 | marketbeat.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Consensus Recommendation of "Hold" by BrokeragesApril 18, 2026 | marketbeat.comAnalysts Conflicted on These Healthcare Names: Rocket Pharmaceuticals (RCKT), Merit Medical Systems (MMSI) and Vaxcyte (PCVX)April 16, 2026 | theglobeandmail.comRocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Short Interest UpdateApril 16, 2026 | marketbeat.comRocket Pharmaceuticals (NASDAQ:RCKT) Shares Pass Below 50-Day Moving Average - Here's What HappenedApril 9, 2026 | marketbeat.comRCKT Stock Down Despite FDA Nod to Gene Therapy in Rare DiseaseMarch 30, 2026 | zacks.comWhy Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADIMarch 29, 2026 | insidermonkey.comRocket Pharmaceuticals, Inc. (RCKT) Discusses FDA Approval of KRESLADI Gene Therapy for Severe Leukocyte Adhesion Deficiency Type 1 TranscriptMarch 27, 2026 | seekingalpha.comRocket Pharmaceuticals secures FDA approval for gene therapy KRESLADIMarch 27, 2026 | proactiveinvestors.caPRocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)March 27, 2026 | joplinglobe.comJRocket’s Gene Therapy Wins FDA Greenlight, Clearing Way for Future ProductsMarch 27, 2026 | biospace.comBRocket Pharmaceuticals (RCKT) Stock Surges After FDA Approves Groundbreaking Gene TherapyMarch 27, 2026 | blockonomi.comRocket Pharma shares climb as FDA approves first therapy for deadly childhood disorderMarch 27, 2026 | reuters.comRocket Pharmaceuticals Launches New $100M At-The-Market ProgramMarch 10, 2026 | tipranks.comRocket Pharmaceuticals, Inc. (RCKT) Presents at Leerink Global Healthcare Conference 2026 TranscriptMarch 10, 2026 | seekingalpha.comWhy Rocket Pharmaceuticals, Inc.’s (RCKT) Stock Is Down 5.28%March 9, 2026 | aaii.comACanaccord Genuity Sticks to Their Buy Rating for Rocket Pharmaceuticals (RCKT)March 9, 2026 | theglobeandmail.comRocket Pharmaceuticals, Inc. (RCKT) Presents at TD Cowen 46th Annual Health Care Conference TranscriptMarch 6, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?By Thomas Hughes | April 29, 2026This 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson | April 20, 20263 Energy Stocks to Buy and 2 to Avoid as AI Power Demand ExplodesBy Bridget Bennett | May 4, 2026The $880M Bet to Survive Real Estate's ResetBy Jeffrey Neal Johnson | April 28, 2026A Quiet Outperformer With a Catastrophe CaveatBy Peter Frank | April 14, 2026AADI, RCKT, ALT, and NAGE Company DescriptionsAadi Bioscience NASDAQ:AADI$3.97 +0.03 (+0.76%) As of 05/8/2026Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Altimmune NASDAQ:ALT$3.09 +0.05 (+1.64%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.08 -0.01 (-0.49%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Niagen Bioscience NASDAQ:NAGE$4.17 -0.02 (-0.48%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$4.19 +0.02 (+0.48%) As of 05/8/2026 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm’s proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.Rocket Pharmaceuticals NASDAQ:RCKT$3.63 -0.04 (-1.09%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$3.64 +0.01 (+0.28%) As of 05/8/2026 07:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
